The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Support side: 10% holder buying, Insider buying cluster — insiders or holders bought while this setup is live; see the timeline.
Radar 95 (high attention) · dilution pressure high · listing risk high · governance risk high · runway 0.8 mo · strongest signal: Restatement (non-reliance) (Aug 14, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going concern in 8-k, runway < 6 months) coexists with live selling machinery (atm program, equity line, pipe). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
On August 14, 2026, HCW Biologics filed an Item 4.02 non-reliance 8-K announcing that its Q1 2026 earnings-per-share calculation was materially misstated due to incorrect application of the two-class method for participating warrants; reported EPS of $2.19 overstated the correct figure by $0.80 per share (post-split basis). The company disclosed a material weakness in controls over technical accounting for complex warrant instruments. Concurrently, the company filed Q2 2026 results showing liquidity of $741,324 as of June 30, 2026—implying under one month of runway at current burn—and reported facing a Nasdaq hearings panel for listing deficiencies.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Restatement (non-reliance) | 8-K Item 4.02 filed 2026-08-14 (accepted 11:00 ET) filing | 69 |
| Aug 14, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (EX-99.1) filed 2026-08-14 filing | 52 |
| Aug 14, 2026 | ▼ PIPE | “pipe” language in 8-K (EX-99.1) filed 2026-08-14 filing | 36 |
| Aug 14, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-08-14 filing | 32 |
| Aug 14, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-99.1) filed 2026-08-14 filing | 32 |
| Aug 14, 2026 | ▼ Going concern in 8-K | “going concern 8k” language in 8-K (EX-99.1) filed 2026-08-14 filing | 31 |
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q/A (10-Q/A) filed 2026-08-14 filing | 16 |
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing | 16 |
| Jul 29, 2026 | ▼ Equity line | “equity line” language in 8-K (EX-10.1) filed 2026-07-29 filing | 51 |
| Jul 29, 2026 | ▲ Insider buying cluster | 3 open-market buys by 3 insider(s) (~$99,993) in 30d: Flowers Lee 7,[email protected] 2026-07-29; Wong Hing C 23,[email protected] 2026-07-29; GARRETT SCOTT T 7,[email protected] 2026-07-29 filing | 45 |
| Jul 29, 2026 | ▼ ATM program | “atm” language in 8-K (EX-10.1) filed 2026-07-29 filing | 44 |
| Jul 29, 2026 | ▲ 10% holder buying | 10% holder open-market purchases: Wong Hing C 23,[email protected] filing | 42 |
| Jul 29, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-07-29 (accepted 17:12 ET) filing | 34 |
| Jul 29, 2026 | ▼ PIPE | “pipe” language in 8-K (8-K) filed 2026-07-29 filing | 33 |
| Jul 29, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-4.1) filed 2026-07-29 filing | 32 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~0.8 months runway: liquidity $741,324 as of 2026-06-30, burn $11,236,655/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 49 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $6,200,000 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 25 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $741,324 vs current liabilities $18,648,173 filing | 21 |
VIVS VivoSim Labs, INC. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · OTLK Outlook Therapeutics, Inc. · screener →